PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

MJM Uijen, YHW Derks, RIJ Merkx… - European journal of …, 2021 - Springer
In the past decade, a growing body of literature has reported promising results for prostate-
specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate …

A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials

E Cruz Da Silva, MC Mercier, N Etienne-Selloum… - Cancers, 2021 - mdpi.com
Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

PSMA expression in solid tumors beyond the prostate gland: ready for theranostic applications?

C Lauri, L Chiurchioni, VM Russo, L Zannini… - Journal of Clinical …, 2022 - mdpi.com
In the past decades, the expanding use of prostate-specific membrane antigen (PSMA)
imaging for prostate cancer has led to the incidental detection of a lot of extra-prostatic …

PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical …

A Holzgreve, A Biczok, VC Ruf… - Frontiers in …, 2021 - frontiersin.org
Aim The aim of the current study was to enlighten the evolution of prostate-specific
membrane antigen (PSMA) expression in glioblastoma between initial diagnosis and …

A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer

S Brunello, N Salvarese, D Carpanese, C Gobbi… - Molecules, 2022 - mdpi.com
Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor
nuclear molecular imaging as an excellent target for both the diagnosis and therapy of …

[PDF][PDF] PSMA expression on neovasculature of solid tumors

C Van de Wiele, M Sathekge… - Histology and …, 2020 - lirias.kuleuven.be
The use of prostate specific membrane antigen (PSMA) binding agents, labelled with
diagnostic and therapeutic radio-isotopes is opening the potential for a new era of …

68Ga–Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme?

J Kunikowska, R Kuliński, K Muylle… - Clinical Nuclear …, 2020 - journals.lww.com
Background Glioblastoma multiforme (GBM) is the most common and most aggressive
primary tumor of the brain. After initial therapy and total resection of GBM, 80% to 90% of …

Differential uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in low-grade versus high-grade gliomas in treatment-naive patients

P Verma, G Malhotra, A Goel, S Rakshit… - Clinical nuclear …, 2019 - journals.lww.com
Results FDG PET/CT showed distinct FDG uptake in high-grade gliomas, whereas low-
grade gliomas were non-FDG-avid amidst physiological tracer uptake. In vivo PSMA …

Recent pre-clinical advancements in nuclear medicine: pioneering the path to a limitless future

W Echavidre, D Fagret, M Faraggi, V Picco… - Cancers, 2023 - mdpi.com
Simple Summary This review summarizes recent advances in the nuclear medicine
theranostic approach. It covers the repurposing of historical radiotracers for new indications …

Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-κB signaling pathway

Y Gao, H Zheng, L Li, M Feng, X Chen… - Frontiers in Cell and …, 2021 - frontiersin.org
Background Glioblastoma multiforme (GBM) is the most common primary malignant tumor in
the central nervous system (CNS), causing the extremely poor prognosis. Combining the …